NEW YORK (GenomeWeb News) – BG Medicine said today that revenues for the second quarter increased 181 percent year over year, surpassing the consensus Wall Street estimates on the top and bottom line.

For the three months ended June 30, the Waltham, Mass.-based company recorded $622,000 in revenues, up from $221,000 a year ago, beating the average analyst estimate of $520,000. Product revenues spiked to $566,000 from $46,000 a year ago, "reflecting increasing demand for the BGM Galectin-3 test," BG Medicine said, while service revenues dropped to $56,000 from $175,000.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: spatiotemporal study of lncRNA expression, role of extrachromosomal, circular DNAs in yeast, and more.

A European team has launched a four-year study to develop a test to gauge cervical, ovarian, uterine, or aggressive breast cancer risk in women.

As interest in personalized medicine grows, government contractors are entering the field, the Washington Post reports.

The New York Times editorial board weighs in on scientific research misconduct.